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Abstract
While the health risks associated with adult cigarette smoking have been well described, effects of 
nicotine exposure during periods of developmental vulnerability are often overlooked. Using 
MEDLINE and PubMed literature searches, books, reports and expert opinion, a transdisciplinary 
group of scientists reviewed human and animal research on the health effects of exposure to 
nicotine during pregnancy and adolescence. A synthesis of this research supports that nicotine 
contributes critically to adverse effects of gestational tobacco exposure, including reduced 
pulmonary function, auditory processing defects, impaired infant cardiorespiratory function, and 
may contribute to cognitive and behavioral deficits in later life. Nicotine exposure during 
adolescence is associated with deficits in working memory, attention, and auditory processing, as 
well as increased impulsivity and anxiety. Finally, recent animal studies suggest that nicotine has a 
priming effect that increases addiction liability for other drugs. The evidence that nicotine 
adversely affects fetal and adolescent development is sufficient to warrant public health measures 
to protect pregnant women, children, and adolescents from nicotine exposure.
Keywords
nicotine; electronic nicotine delivery systems; priority/special populations
1. Background
After decades of declining cigarette sales, cigarette companies expanded their product lines 
to include a range of nicotine-containing products with varying levels of toxicity, including 
smokeless tobacco in the 1990s, and electronic cigarettes and other types of electronic 
nicotine delivery systems (ENDS) in the early 2000s. Some tobacco companies have also 
added nicotine replacement therapy (NRT) pharmaceuticals.(1-3) Electronic cigarettes–
devices which create an aerosol for inhalation by heating a liquid solution that typically 
contains propylene glycol and/or glycerin, flavorings, and nicotine–have experienced rapid 
growth since their introduction into the US market.(4-6) However, their arrival has also 
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engendered debate in the public health community.(7, 8) Those concerned about the risks 
from electronic cigarettes to individual and population level health note that electronic 
cigarettes could perpetuate conventional cigarette use in smokers who use both products 
instead of quitting cigarettes completely, and that adolescent users of these products could 
progress to conventional cigarette use.(4, 9, 10) In contrast, others contend that electronic 
cigarettes have lower toxicity than conventional cigarettes, higher consumer appeal than 
NRT, and that their use may lead to cessation or to a reduction in toxicant exposure, thereby 
reducing the burden of tobacco-related death and disease.(11)
A key assertion advanced by those in favor of wide access to electronic cigarettes is that 
nicotine exposure presents a minimal health risk for most adult tobacco users.(12) This is 
based, in part, on longitudinal studies of adults exposed to nicotine from smokeless tobacco 
or NRT, which found lowered risk for myocardial infarction, stroke, and lung cancer 
compared with risk in cigarette smokers.(13-16) However, this assertion has important 
limitations. Electronic cigarette use is not limited to adults or to conventional cigarette 
smokers.(17) Use has increased dramatically in high school and middle school students 
since 2011, (5) and in 2014, twice as many youth used electronic cigarettes alone as in 
combination with cigarettes.(18) Furthermore, as will be presented here, conclusions about 
the risks of nicotine exposure based on studies in adults cannot be extrapolated to 
adolescents or pregnant women and their fetuses, because these populations have health 
risks unique to their particular stages of development. Nevertheless, discussions of the 
potential adverse health effects of nicotine among pregnant women and adolescents are often 
absent from discussions related to the public health impact of electronic cigarettes.
In May of 2015, scientists from varied disciplines were convened by the National Institutes 
of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to review the 
scientific literature on the health effects of nicotine exposure during periods of 
developmental vulnerability. In this expert review, meeting participants used MEDLINE and 
PubMed literature searches, books, reports, and expert opinion to summarize and synthesize 
relevant epidemiological, clinical, and preclinical research on the health effects of exposure 
to tobacco and nicotine pregnancy and adolescence. Electronic cigarettes were introduced to 
markets relatively recently, and their effects on health outcomes in pregnant women and 
adolescents have not been directly assessed. In addition, there are no published studies of 
developmental outcomes using animal models nicotine exposure from electronic cigarettes. 
Therefore, the authors draw on studies of other forms of tobacco exposure (cigarettes and 
smokeless tobacco) in humans and conventional nicotine exposure in animals. While there is 
evidence from animal models that gestational nicotine exposure also affects several organ 
systems, including renal, hematopoietic, adipose and endocrine,(19-23) we focused on the 
central nervous and pulmonary systems, which are the most established and clearest targets 
of nicotine. In addition, shorter-term studies of exposures to electronic cigarette-derived 
aerosols in adult mouse models demonstrate that electronic cigarettes can produce 
pulmonary and behavioral effects similar to those seen with conventional nicotine exposures.
(24-27)
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The implications of the increasing use of nicotine-containing products, specifically 
electronic cigarettes, for pregnant women and adolescents are discussed, and potential 
strategies for minimizing exposure in these populations are presented.
2. Tobacco use and nicotine exposure during pregnancy
2.1 Pregnancy outcomes
Maternal cigarette smoking during pregnancy is causally associated with a number of 
adverse pregnancy outcomes, including ectopic pregnancy, fetal growth restriction, preterm 
birth, placental abruption, and orofacial cleft defects.(15) Despite high awareness that 
smoking increases the risk of pregnancy complications,(28) over 10% of U.S. women smoke 
cigarettes during pregnancy, exposing more than 400,000 fetuses each year.(29) Tobacco 
smoke contains thousands of chemicals, many of which could contribute to adverse 
outcomes.(30) However, studies of pregnant women who are exposed to nicotine without 
products of combustion through the use of smokeless tobacco products can provide insight 
into the potential role of nicotine. These studies have found associations with preterm birth, 
stillbirth, and orofacial cleft defects,(15, 31-35) but no clear association with fetal growth 
restriction.(36-39) In agreement with the latter finding, animal models utilizing nicotine 
alone do not demonstrate any consistent effect on fetal growth at exposures modeling those 
in typical smokers.(40-42) Together, these findings provide evidence that nicotine and other 
tobacco smoke components produce distinctive adverse pregnancy outcomes.
2.2 Fetal brain development
During development, neurotransmitters control and coordinate the cellular and architectural 
assembly of the central nervous system.(43, 44) At the appropriate developmental phase, 
stimulation of neurotransmitter receptors regulates brain assembly by (1) promoting cell 
replication; (2) initiating differentiation; (3) initiating and then terminating axonogenesis and 
synaptogenesis; (4) regulating cell death; and (5) promoting cell migration to specific brain 
regions.
Acetylcholine plays a critical role in brain maturation via activation of nicotinic 
acetylcholine receptors (nAChRs). These receptors are a structurally diverse family of 
ligand-gated ion channels which regulate synaptic plasticity and brain development. 
Nicotine crosses the placenta(45) and specifically binds to nAChRs in the fetal brain.(46, 47) 
Since nAChRs are functional at early stages of brain development, their early activation 
and/or desensitization by nicotine can lead to long-term developmental disruption.(48-50) 
Even first-trimester exposure can induce disruption of brain development at both cellular and 
structural levels.(51) Although the structural features may appear grossly normal by early 
adulthood,(52) a detailed analysis of synaptic architecture shows long-lasting alterations 
(layer thinning, loss of neuropil, glial “scarring”), particularly in the hippocampus and 
somatosensory cortex areas that are critical for attention and cognitive function.(52-54) 
Thus, from a morphological standpoint, nicotine is a subtle neuroteratogen. However, its 
functional consequences exceed the visible evidence of disrupted development.
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In developing rats exposed prenatally to nicotine at plasma levels comparable to those in 
human active smokers, standard biomarkers of cell injury indicate apoptosis, reductions in 
the numbers of neuronal cells, truncation of axonogenesis, and deficient synaptogenesis.
(55-58) Neuronal damage and cell loss involving the activation of genes associated with 
apoptosis intensify in the postnatal period despite the discontinuation of nicotine exposure.
(57, 59, 60) The developmental context is critical for evoking damage, since nicotine-
induced apoptosis in the immature brain is distinct from its effect in the mature brain.(61, 
62) For example, hippocampal progenitor cells show nicotine-induced apoptosis only during 
early differentiation.(63) Furthermore, the delayed-onset changes that occur when nicotine is 
no longer present in the system indicate that nicotine changes the entire trajectory of brain 
development so that adverse effects can emerge later in life, after a period of apparent 
normality. This is particularly important for patterns of synaptic activity that display initial 
deficits in the early postnatal period, but tend to recover by juvenile stages, only to show a 
reemergence of hypoactivity in adolescence,(59, 64-66) at which point there is a persistent 
deficit in nAChR function.(67-70)
To characterize the involvement of nAChRs in regulating brain development during the third 
trimester human fetal period, studies examined the effects of nicotine exposure during the 
functionally-equivalent early postnatal period in rats and found altered thalamocortical 
maturation, resulting in subsequent impairment of cognitive behaviors.(67, 71, 72) The 
hippocampus and cerebellum, which are both late maturing structures, also exhibited unique 
regulation by nAChRs,(73-76) and consequently, postnatal nicotine exposure disrupted 
morphological assembly of these regions.(77, 78) Thus, animal studies indicate that nicotine 
exposure can negatively impact all stages of fetal brain development. Indeed, it is estimated 
that nicotine is responsible for as much as 36%-46% of the overall impact of tobacco smoke 
on the development of brain circuitry in animal models.(79)
It is important to note that the adverse effects of nicotine on brain development occur at 
exposure levels that do not compromise somatic growth.(64) Maternal cigarette smoking is 
strongly associated with intrauterine growth retardation, a well-recognized predictor of poor 
perinatal outcomes.(15) However, because nicotine targets the fetal brain, damage can be 
present, even when birth weight is normal. This reflects the specific actions of nicotine on 
nAChRs that modulate neuronal development, in contrast to non-specific fetal insults, which 
typically spare brain development at the expense of fetal somatic growth.(64, 80, 81)
The effects of isolated nicotine exposure on human fetal brain development have not been 
studied directly. However, maternal cigarette smoking has measurable effects on brain 
structure that are consistent with animal models that evaluated nicotine alone. Imaging 
studies found that fetuses exposed to maternal smoking had decreased transcerebellar and 
lateral ventricle diameter/width (ultrasound) and decreased overall brain volume (MRI) 
compared with unexposed fetuses, as well as smaller frontal lobe and cerebellar volumes in 
infancy.(82-84) Imaging studies of offspring in later life also found differences in the brains 
of exposed offspring, including reduced cerebral cortical gray matter, reduced subcortical 
gray matter volumes in the amygdala, thalamus, and pallidum, and reduced volume in the 
corpus callosum.(85-90) In a study of 6- to 8-year-old children prenatally exposed to 
maternal smoking, the authors found reduced brain volume, smaller cortical gray and white 
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matter volumes, and thinning of the superior frontal, superior parietal, lateral occipital, and 
precentral cortices compared with age- and gender-matched unexposed children.(91) Taken 
together, studies of tobacco exposure in human fetuses are in agreement with those of 
nicotine exposure in animals, and in particular, those which documented disruption of brain 
development independent of effects on fetal growth.(83, 89, 91) The structural alterations 
seen in human studies are paralleled by functional changes in the fetus. Studies using real-
time fetal monitoring(92-95) found greater rates of maladaptive response to the non-stress 
test (a clinical index of fetal well-being)(96), including reduced heart rate variability, 
increased mouth and self-touch movements, and impaired recognition of maternal voice in 
fetuses of smokers compared with those of nonsmokers.(97-99)
2.3 Perinatal mortality and sudden infant death syndrome
Maternal smoking during pregnancy increases the risk of perinatal mortality (which includes 
both stillbirth and neonatal death) by 20-30%,(100) and of sudden infant death syndrome 
(SIDS) 2.4 to 3-fold.(101) Maternal smokeless tobacco use in pregnancy is associated with a 
1.6 to 2.6-fold increase in stillbirth.(31, 33)
Maternal smoking is thought to increase perinatal mortality and SIDS risk in part through its 
effects on fetal and infant stress responses. Human parturition is associated with an extended 
period of hypoxia, and the fetus and newborn possess unique adaptive responses that 
maintain cardiovascular function during this period. These responses center around 
circulatory adjustments that ensure adequate perfusion of the brain and heart, and require 
autonomous secretion of catecholamines from the adrenal medulla (102), as well as a 
myocardium that is adapted to function in a low oxygen environment.(103, 104) Prenatal 
nicotine exposure leads to severe reduction or loss of the adrenomedullary component, along 
with a reduced cardiac response to adrenergic stimulation, resulting in brain injury or death 
during a hypoxic episode that would ordinarily not be harmful.(59, 60, 105) Although 
animal studies provide the primary evidence for this mechanism, the same deficiency in 
adrenomedullary function in response to hypoxia has been identified in the offspring of 
smokers at birth.(106) The loss of cardiovascular adaptation caused by maternal smoking 
affects the fetus during delivery, when hypoxic events can evoke stillbirth or birth asphyxia, 
as well as during infancy, when hypoxic events can result in SIDS.(107)
Additional contributions of maternal smoking to SIDS risk likely entail effects on central 
cardiorespiratory control and arousal. Maturation of sleep architecture and sleep during the 
first year of life includes changes in both respiratory and cardiovascular control.(108) 
Infants, especially those born preterm, are at increased risk for cardiorespiratory 
disturbances, apnea, and hypoxemia during sleep, events for which arousal is an important 
protective response. Failure of this response mechanism could contribute to SIDS risk.
(109-111) Maternal smoking and smokeless tobacco use during pregnancy are associated 
with increased risk of neonatal apnea, while maternal smoking is also associated with a 
decreased arousal response.(109, 112-118) The administration of nicotine to pregnant ewes 
can evoke the same deficit in newborn lambs.(119) In addition, there is evidence that 
prenatal nicotine exposure damages brainstem circuits that are responsible for mounting 
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appropriate respiratory responses to neonatal hypoxia, which could contribute to additional 
SIDS risk.(120, 121)
2.4 Infant stress response
Maternal smoking during pregnancy in humans leads to alterations in behavior and stress 
responsiveness in newborns, in addition to the specific effects on hypoxic stress discussed 
above. Specifically, studies of the immediate neonatal period (postnatal days 1-5) revealed 
increased signs of abstinence/withdrawal, hypertonicity, irritability, and excitability in 
tobacco-exposed neonates, with a clear dose-response relationship to nicotine exposure.
(122-126) Studies later in the neonatal period (10-30 days) found continued or emerging 
behavioral effects on self-regulation, attention, need for external soothing or handling, and 
arousal—all potentially portending longer-term effects on attention and regulation.(127-129) 
Several studies also found alterations in stress responses in exposed infants. For example, 
the stress hormone, cortisol, was increased in the cord blood of newborns of smoking 
mothers,(130-132) and infants aged 1-7 months showed altered cortisol response to stress.
(133-135) There is extensive scientific literature on the long-term neurobehavioral deficits 
associated with early life exposure to prolonged stress and/or excessive glucocorticoid 
hormones (reviewed by Maccari et al, 2003).(136) Similarly, animal studies found evidence 
that prenatal nicotine exposure disrupts stress hormone regulation in offspring.(137-139) For 
example, in one study, adult male rats with gestational exposure to nicotine showed 
abnormal neuroendocrine responses to stress.(137)
2.5 Auditory processing
A number of studies have examined maternal smoking and infant auditory processing.
(140-143) Healthy newborn infants of non-smoking mothers discriminated among a greater 
number of syllables whereas healthy newborns of smokers began the discrimination process 
at least 150 msec later and differentiated fewer stimuli.(144) Effects on auditory processing 
may persist beyond infancy; an increased risk of low-frequency hearing loss has been 
documented in adolescent offspring of women who smoked during pregnancy.(145) Animal 
research supports that nicotine adversely affects auditory processing.(71, 146) Exposure of 
rats to nicotine in the second postnatal week, corresponding to the third trimester of human 
fetal brain development,(147) disrupted the development of glutamate synapses in the 
auditory cortex, which has been associated with long-term deficits in auditory processing 
and learning.(67, 71)
2.6 Outcomes in childhood and adolescence
Numerous studies have addressed the long-term consequences of maternal smoking during 
pregnancy on offspring behavior. The most consistent associations are with externalizing and 
disruptive behaviors, such as conduct disorder (antisocial personality disorder in adults) and 
oppositional defiant disorder, from infancy through adulthood, as well as the precursors of 
these behaviors.(148, 149) However, a major limitation of traditional approaches to studies 
of prenatal tobacco exposure and behavioral outcomes has been the inability to fully control 
for potential confounding factors, particularly family environment and genetic factors.(150) 
More recently, high quality, prospective studies using multimethod exposure measurement 
and propensity score modeling have delineated a coherent pattern of disruptive behavior 
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associated with prenatal tobacco exposure, beginning in early childhood.(151, 152) For 
example, adoption studies provide support for an independent effect of maternal smoking 
during pregnancy on externalizing behaviors.(151) A recent sibling study that included 
detailed exposure data and careful control for family-level effects found modest, but 
statistically significant associations between tobacco exposure and conduct disorder 
symptoms and oppositional defiant disorder symptoms.(153) Both associations were similar 
in magnitude to contributions from genetics and family environment described in prior work. 
These studies add evidence supporting a role for prenatal tobacco exposure in increased risk 
for externalizing behaviors.
Associations have also been described between maternal smoking during pregnancy and 
offspring internalizing behaviors (anxiety and depression), attention deficit hyperactivity 
disorder (ADHD), and impairments in learning and memory, but are less consistent than for 
externalizing behaviors.(150, 154-176) These inconsistencies illustrate the difficulty in 
determining cause-and-effect relationships for different outcomes in diverse human 
populations with multiple confounders and risk factors for neurobehavioral deficits, 
especially when the associated behavior may not emerge for years after the injurious 
exposure.
Animal models have been used to assess the role of prenatal nicotine exposure on 
developmental and long-term behavioral outcomes. Reflex behaviors characterize the 
development of sensory and motor systems in the brain, and rodent studies suggest that 
prenatal nicotine exposure delays maturation of reflexes, including negative geotaxis and 
surface righting (measures of limb coordination and locomotor development), as well as 
causing long-lasting alterations in filtering auditory information. (146, 177-179) However, 
these findings are not entirely consistent; some studies found normal reflex development in 
exposed animals (reviewed by Sobrian and Holson 2011).(180) Activity levels have also 
been studied using rodent models, again with inconsistent results, perhaps reflecting 
differences in the developmental exposure period and the method of nicotine administration, 
or, in some cases, lack of sufficient statistical power in the experimental design.(180)
In contrast, there is greater consistency among animal studies examining the effects of 
prenatal nicotine exposure on cognitive development, suggestive of global impairments in 
learning and memory.(181-190) These effects appear to be dose dependent and sensitive to 
factors such as sex and timing of exposure. Research suggests that these deficits reflect 
effects on nAChR modulation of long-term potentiation in the hippocampus.(187) Adverse 
outcomes on affective behavior have also been identified, including learned helplessness, 
fear trace conditioning, and anhedonia.(191, 192) Combined gestational/neonatal exposure 
is associated with increased anxiety levels, poor adaptation in a new environment, and 
decreased novelty-seeking.(181, 193, 194)
2.7 Pulmonary outcomes
Maternal smoking during pregnancy has adverse effects outside the central nervous system, 
most notably on lung development, causing lifelong decreases in pulmonary function.
(195-199) At birth, and prior to any significant postnatal exposure to tobacco smoke, infants 
born to smokers show decreased pulmonary function tests, with decreased respiratory flows 
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and respiratory compliance, and altered tidal breathing patterns. (198-200) These changes 
lead to increased risk in childhood of wheezing, hospitalization for respiratory infections, 
and asthma.(201-203) Studies of the effects of nicotine on lung development have been 
performed in mice, rats, sheep and monkeys with strikingly similar results between animals 
and humans.(204) In humans, the clearest, most consistently measured effect of maternal 
smoking during pregnancy on offspring respiratory health is decreased forced expiratory 
flow.(195-198) In both monkeys and mice, exposure to prenatal nicotine alone, at levels 
similar to that of smokers, causes similar decreases in forced expiratory flow.(205-207) A 
primary mediator of this effect appears to be the α7 nAChR, as the effect of nicotine was 
lost in α7 nAChR knockout mice.(205)
Studies on non-human primates point to the potential mechanisms of nicotine’s actions on 
lung development. Treatment of pregnant rhesus monkeys with nicotine causes marked 
increases of levels of α7 nAChR in fibroblasts surrounding airways and blood vessels in the 
fetal monkey lung, and increases in collagen in a similar distribution.(208-210) Similar 
effects are seen in mice.(205) The increased collagen and decreased elastin caused by 
prenatal nicotine exposure likely underlies the decreases in lung compliance seen in the 
offspring of smokers. Prenatal nicotine exposure leads to thickening of walls surrounding 
airways and pulmonary vessels in animal models,(209, 210) a finding that has also been 
reported in the human offspring of smokers,(211, 212) along with similar increases in 
connective tissue and α7 expression.(212) In addition, consistent with the long term effects 
on offspring pulmonary function and increased risk of asthma associated with maternal 
smoking during pregnancy in humans, smoking during pregnancy causes long-lasting 
changes in DNA methylation if offspring(213) that are observed in fetal lung,(214) cord 
blood,(214) and which continue to be present in the blood of school-age children.(215) In 
rodent models, prenatal nicotine exposure causes similar DNA methylation changes, 
including changes in Runx1 methylation, which has been associated with increased risk of 
asthma,(216-219) Research by Rehan and colleagues supports that DNA methylation 
changes caused by in utero nicotine exposure may persist for multiple generations.(217, 
218) Rodent models also suggest that prenatal tobacco exposure can cause decreased histone 
deacetylate activity in offspring lung, accompanied by changes in expression of the 
glucocorticoid receptor splice variant 1.7.(220) While the immediate human clinical impact 
of these findings are unclear, they suggest that epigenomic modifications in important 
inflammatory and pulmonary maturation pathways (i.e., glucocorticoid receptors), may 
result from in utero nicotine exposure. Whether this ultimately translates into increased risk 
of asthma and pulmonary atopic disease among offspring remains unknown.
3. Tobacco use and nicotine exposure during adolescence
3.1 Tobacco use during adolescence
Tobacco use among adolescents in the United States is changing rapidly. While the 
prevalence of cigarette smoking has steadily declined over the past decade(18, 221-223), the 
use of alternative tobacco products, including electronic cigarettes, has increased.(224) 
Conventional cigarettes were the most commonly used tobacco products by U.S. youth in 
2013 (225), and many youth who used electronic cigarettes—more than a quarter million—
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had never smoked combustible cigarettes (226). A subsequent survey in 2014 and 2015 
found that past-month e-cigarette use has surpassed conventional cigarette use among 
middle and high school students.(227, 228) Several longitudinal studies have found that 
electronic cigarette use at baseline is associated with increased risk of future use of 
combustible tobacco products.(9, 10, 229, 230)
3.2 Brain development in adolescence
Concerns about nicotine toxicity do not end after birth or infancy. Brain development 
continues well into the third decade of life, and the adolescent and young adult brains differ 
from those of the fully mature adult, both physiologically and neurochemically. For 
example, adolescent synapses are more numerous and more “plastic,” or moldable by 
experience.(231-233) Hence, adolescents have superior learning and memory skills 
compared to adults, with synaptic formation and learning highly strengthened by stimulation 
from environmental experience.(234) This feature of adolescent brain development can have 
detrimental consequences when inappropriate stimulation is evoked by exposure to 
neuroactive chemicals. For example, addictive stimuli or drugs can activate and strengthen 
reward circuits to create an addicted state.(235) Adolescents and young adults are thus more 
vulnerable to addiction than adults.(223) In support of this, epidemiologic studies document 
that individuals who begin smoking as teens are more likely to become life-long smokers 
than those who start smoking in their 20’s or later.(236-238) Furthermore, adolescents 
experience symptoms of dependence at lower levels of nicotine exposure than adults.
(239-241) Consequently, it is harder to reverse addiction originating in this stage compared 
with later in life.(242) Animal studies confirm the heightened response of adolescents to 
nicotine exposure.(243) Adolescent rodents self-administer nicotine more than adults and 
adolescent exposure leads to increased self-administration of nicotine (244) and other drugs 
in adulthood.(245)
The special vulnerability of the adolescent brain extends to areas involved in higher 
cognitive function, such as the prefrontal cortex where circuit formation continues into the 
20s. During this extended maturational period, substantial neural remodeling occurs in a 
variety of pathways, including those governed by dopamine or acetylcholine. Dopamine is 
critical to reward function, and acetylcholine plays a central role in cognitive maturation, 
including executive function mediated by the prefrontal cortex.(246)
Functional magnetic resonance imaging (fMRI) has been used in numerous studies of adult 
smokers to examine the neural circuitry involved in nicotine craving and addiction,(247-255) 
but in fewer studies of adolescent smokers.(256-261) Peters et al. examined neural responses 
to anticipation of financial reward in adolescent smokers (age 14 years)(262) and found that 
they had smaller neural responses in the ventral striatum and midbrain compared to matched 
non-smoking controls. Moreover, the reduced response showed a clear-cut relationship with 
the frequency of smoking. These findings suggest that adolescent smokers display a hypo-
responsivity to the anticipation of non-drug reward (i.e., financial reward) relative to non-
smokers, and this hypo-responsivity becomes more severe with increased smoking. There is 
also evidence that adolescents who smoke ≤5 cigarettes per day display attenuated responses 
to other non-drug rewards, including pleasurable food images, relative to non-smokers, in 
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areas including the insula and inferior frontal region.(256) The implication of both these 
studies is that the use of extremely rewarding drugs, such as nicotine, may decrease the 
perception of the pleasure obtained from non-drug rewards. Furthermore, the fact that this 
was demonstrated in young- and light-smoking teens indicates that such changes in the brain 
occur in early phases of smoking.
3.3 Cognitive outcomes
Nicotine withdrawal produces transient cognitive impairment and negative affective states, 
while smoking relapse alleviates these symptoms (reviewed by Hall et al., 2015).(263) In 
addition, adult smokers show more rapid cognitive decline with age than nonsmokers,
(264-268) although it is unclear whether the underlying mechanisms involve nicotine, 
products of combustion, or both.(15) The few studies that have been done in adolescents and 
young adults also suggest that cigarette smoking has adverse effects on cognition.(269-271) 
For example, one study found that current smokers aged 17-21 who smoked throughout their 
adolescence performed significantly worse than their nonsmoking counterparts on a variety 
of neurocognitive tasks, even after adjustment for educational attainment and family income.
(271) In a separate study of adolescent daily smokers and nonsmokers who were similar in 
age, sex, and education, smokers showed impairments in accuracy of working memory 
performance, irrespective of recency of smoking.(269) Earlier age at onset of smoking was 
associated with more severe performance decrements, and smokers experienced depressed 
mood and further disruption of working memory and verbal memory during abstinence. 
Furthermore, male smokers initiated smoking at an earlier age than females and were more 
impaired during tests of selective and divided attention than female smokers and 
nonsmokers. Abstinent adolescent smokers have also been found to exhibit reductions in the 
efficiency of their working memory neurocircuitry.(270) In a study of adolescent smokers 
and non-smokers who were similar with respect to age, education, IQ, parental education, 
and symptoms of inattention, prenatal and adolescent exposure to tobacco smoke were both 
associated with increased fractional anisotropy in anterior cortical white matter.(258) 
Disruption of auditory corticofugal fibers may interfere with the ability of these fibers to 
modulate ascending auditory signals, leading to greater noise and reduced efficiency of 
neurocircuitry that supports auditory processing. In a study of young adult non-abstinent 
smokers and non-smokers age 18-29 years who were matched for age, education, income, 
and sex, smokers showed significant cognitive impairments in sustained attention, spatial 
working memory, and executive planning.(272) In a study of young adults age 18-35 years, 
the authors found prefrontal attentional network activity was reduced in smokers compared 
with non-smokers using fMRI, and the degree of diminished attentional network activity was 
correlated with the number of years participants had smoked.(273) Finally, cognitive deficits 
have also been associated with childhood and adolescent exposure to secondhand cigarette 
smoke.(274, 275)
The association between adolescent cigarette smoking and long-lasting deficits in cognition 
is especially troubling because several mental health disorders that include changes in 
cognition are also associated with higher rates of tobacco use.(276-283) For example, an 
elevated prevalence of cigarette smoking has been noted among individuals with 
schizophrenia, ADHD, depression, anxiety disorders, bipolar disorder, and others.(284, 285) 
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There is evidence to support a bidirectional relationship—attributes that predispose 
individuals to these conditions could also predispose them to tobacco use and nicotine use—
and addiction could result in or exacerbate symptoms accompanying these disorders.(263, 
286) Similar phenomena could occur in individuals with subclinical affective or cognitive 
disorders.(263)
Existing human studies of cognitive outcomes are mainly cross-sectional in nature, making 
it difficult to determine whether tobacco use results from premorbid cognitive problems or 
causes these problems. However, studies of laboratory rodents provide strong evidence that 
isolated nicotine exposure during adolescence produces long-lasting deficits in learning and 
cognitive processes.(182, 287-290) For example, adolescent nicotine exposure was 
associated with adult deficits in contextual fear conditioning, but not cued fear conditioning, 
in both rats and mice,(288) suggesting altered function in brain regions involved in 
contextual processing, such as the hippocampus. In support of altered hippocampal function, 
adolescent nicotine exposure was associated with reduced hippocampal CA1 dendritic 
length and apical dendritic branch complexity. (291) The effects on learning were not seen in 
adults similarly exposed to nicotine.(182) In addition, adult rats exposed to nicotine during 
adolescence had deficits in attention and displayed increased impulsivity.(292) These 
cognitive deficits may be related to long-lasting changes in cellular processes involved in 
synaptic plasticity, as adolescent nicotine exposure altered adult medial prefrontal cortical 
long-term potentiation of synaptic activity.(289)
Animal studies also provide evidence for long-lasting changes in mental health-related 
behaviors after adolescent nicotine exposure.(293-295) For example, adolescent nicotine 
exposure increased anxiety in adult rats,(296) decreased the sensitivity to natural rewards, 
and fostered depression-like behaviors.(295) Further, changes in anxiety related to 
adolescent nicotine exposure were associated with increased corticotropin-releasing factor, a 
neuropeptide involved in stress response initiation, in the hypothalamus and frontal cortex 
and frontal cortex and increased neuropeptide Y, a neuropeptide that may play a protective 
role in responses to stress, in the hypothalamus and hippocampus.(297) Together, these 
findings raise serious concerns about the long-term impact of adolescent nicotine exposure 
on mental health through adverse effects on cognition, anxiety, impulsivity, depression, and 
drug reward and reinforcement.
3.4 Trajectory of tobacco and other substances use
There is evidence that nicotine exposure in adolescence affects the use of other substances. 
In the U.S. population, the use of tobacco often precedes the use of other drugs including 
marijuana, which in turn generally precedes the use of cocaine and other illicit substances 
for those who go on to use other drugs.(298-300) Although this pattern may reflect that 
tobacco is legal and easier to access than illicit substances, evidence from translational 
research in rodents supports a causal mechanism for the observed sequence of progression 
from tobacco to other drugs. Nicotine pretreatment in mice and rats enhances the subsequent 
response to cocaine, but the effect is unidirectional, as the reverse order (cocaine followed 
by nicotine) does not result in enhancement of the response to nicotine.(301-303) At the 
molecular level, nicotine exerts a priming effect by enhancing the ability of cocaine to 
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induce FosB, a key mediator of addiction.(304, 305) It does so by inhibiting histone 
deacetylation. The consequent enhancement of gene expression leads to an increase in the 
response to cocaine in reward-based areas. These results provide a biological basis and a 
molecular mechanism for nicotine as a gateway drug.
4. Synthesis and conclusions
Historically, many clinicians and scientists have considered exposure to nicotine alone to be 
low risk, especially for established smokers. However, for pregnant women and adolescents, 
a large body of scientific evidence challenges this concept. As detailed in this review, 
existing human and animal research provides sufficient evidence for researchers and public 
health officials to draw a number of conclusions regarding the adverse effects of nicotine on 
human development. These conclusions could serve as a foundation for public health policy, 
planning, and practice regarding electronic cigarettes and other non-combustible tobacco 
products.
Animal models of prenatal nicotine exposure have successfully recapitulated the 
neurodevelopmental and behavioral phenotypes associated with maternal cigarette smoking 
during pregnancy,(55-57, 64, 306) and these studies show that nicotine itself is a critical 
contributor to the harmful neurodevelopmental effects of tobacco smoke exposure.(307-310) 
Similarly, the combined results from animal and human studies of prenatal cigarette and 
nicotine exposure provide consistent evidence that fetal nicotine exposure adversely affects 
lung development in utero, in infancy, and in childhood.(204) It is likely that the use of 
nicotine-containing products by pregnant women, including electronic cigarettes, will have 
effects on pulmonary development that are similar to those observed in the offspring of 
cigarette smokers. While there is evidence of variability in nicotine delivery across devices 
and users,(311, 312) evidence suggests that some electronic cigarette products may deliver 
as much nicotine as conventional cigarettes.(313, 314) Because lung development in utero 
and in childhood contributes to life-long trajectories of lung function, the effects of prenatal 
exposure to nicotine could have negative effects on respiratory health in middle-aged and 
older adults, including increased risk of asthma and chronic obstructive pulmonary disease 
(COPD).(315-317) In addition, human and animal studies of prenatal tobacco and nicotine 
effects on cardiorespiratory function provide strong evidence that fetal nicotine exposure 
compromises the fetal and neonatal response to hypoxic stress, which could contribute to the 
pathophysiology underlying SIDS.
The integration of human and animal studies of behavioral and cognitive outcomes 
associated with nicotine exposure is complex, but also demonstrates areas of close 
alignment. Maternal cigarette smoking in humans and nicotine exposure in animals have 
been consistently associated with auditory processing deficits, which could affect language 
development and speech comprehension. Rigorous studies of prenatal tobacco exposure in 
humans using innovative approaches to address potential confounding from genetic and 
environmental factors have found associations with externalizing behavioral outcomes in 
offspring. Furthermore, animal studies of gestational nicotine exposure provide support for 
the underlying biological mechanisms that could explain deficits observed in humans, 
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notably nicotine’s actions on nAChRs. nAChRs play unique roles in development, and 
exposure to nicotine, even at very low levels, disrupts those developmental processes.
Human and animal studies of adolescent exposure to cigarette smoking and nicotine also 
have areas of convergence. It is well established from human and animal research that 
adolescents are highly vulnerable to addiction to nicotine.(223) More recent animal studies 
demonstrate a “priming” effect of nicotine that increases vulnerability to addiction to other 
drugs. Studies of human adolescent smokers also find deficits in working memory, attention, 
and auditory processing, and adolescent nicotine exposure in rodents is associated with 
deficits in learning and in attention, as well as in increased impulsivity and anxiety. 
Prospective studies of child and adolescent drug exposure, such as the recently launched 
Adolescent Brain Cognitive Development Study,(318) could yield additional data from 
subjects exposed to non-combustible tobacco products, such as smokeless tobacco and 
electronic cigarettes, helping to quantify the effects of nicotine exposure on cognitive, 
behavioral, and mental health outcomes. Finally, nicotine withdrawal in adolescent tobacco 
users can cause impairments in cognition and has adverse effects on mood and attention.
(269-271)
The evidence presented in this review has often been overlooked in discussions about the 
relative harms and risks of electronic cigarettes, perhaps in part because of the paucity of 
studies of isolated nicotine exposure in humans. Randomized trials of nicotine exposure in 
humans that could determine effects of nicotine on development are unethical, so researchers 
rely on observational studies of human smokers. Human smokers, however, are exposed not 
only to nicotine, but to hundreds of other toxic components generated by combustion, such 
as carbon monoxide, acetaldehyde, and polycyclic aromatic hydrocarbons. In addition, there 
are numerous methodological challenges inherent in studies of smokers, including residual 
confounding from socioeconomic, environmental, genetic and other factors. Although 
considerable progress has been made in overcoming these limitations, controlled animal 
experiments remain a critically important supplement to human studies in establishing the 
consequences of nicotine exposure. In fact, rodent models historically have served as the 
“gold standard” for evaluating developmental neurotoxicants,(64, 319) and regulatory 
decisions on product safety are routinely made using animal data. Of particular relevance to 
nicotine is the example of chlorpyrifos, an acetylcholinesterase inhibitor and widely-used 
organophosphate insecticide that leads to inappropriate overstimulation of cholinergic 
receptors similar to that caused by nicotine.(57)1
Despite the strength of data in support of adverse effects of nicotine exposure during 
pregnancy and adolescence, important research gaps remain that, if addressed, could better 
characterize these effects. An improved understanding of how the timing of nicotine 
exposure during pregnancy affects fetal development could lead to more effective strategies 
to limit nicotine’s effects, such as intensified efforts to promote cessation by a specific 
gestational age or prior to conception. Research could also expand our understanding of the 
1In 2002, chlorpyrifos was banned from residential use by the US Environmental Protection Agency based almost entirely on 
neurodevelopmental deficits demonstrated in rodent studies that were explicitly modeled after those conducted for nicotine.(57, 64, 
320)
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relative contributions of nicotine and products of combustion to effects on brain 
development and cognitive outcomes in adolescence. Indeed, several recent studies indicate 
that other tobacco smoke components amplify the adverse effects of nicotine, and that even 
the low levels of nicotine exposure associated with secondhand smoke are injurious to fetal 
brain development and cognitive function.(79, 321, 322)
Recently, important steps were taken that will help protect vulnerable populations from 
exposure to nicotine. The Child Nicotine Poisoning Prevention Act, which requires child-
resistant containers for liquid nicotine e-cigarette cartridges, was signed into law in February 
2016.(323) In May 2016, the U.S. Food and Drug Administration finalized a rule extending 
its authority to all tobacco products, including electronic cigarettes. Federal law will require 
health warnings on electronic cigarette packages and advertisements that read “WARNING: 
This product contains nicotine. Nicotine is an addictive chemical." The law prohibits the sale 
of electronic cigarettes to individuals under the age of 18 years, the sale of electronic 
cigarettes in vending machines, and the distribution of free samples.(324) In the future, 
additional potentially effective strategies could include strong prohibitions on electronic 
cigarette marketing to reduce youth uptake, health warnings specific to pregnant women and 
adolescents, and protection from exposure to secondhand electronic cigarette aerosol. 
Measures could also include consideration of the impact of pricing on youth initiation and 
use; product addiction potential and youth appeal, including youth-oriented flavorings; 
accessibility of products through placement in retail venues; and social networking potential. 
In addition, policies related to the age of legal sale of electronic cigarettes and other 
nicotine-containing products could benefit if informed by our knowledge of the 
developmental stages during which humans are most vulnerable to the adverse effects of 
nicotine. Because the brain does not reach full maturity until the mid-20s,(325) restricting 
sales of electronic cigarettes and all tobacco products to individuals aged at least 21 years 
and older could have positive health benefits for adolescents and young adults. Finally, it is 
important for clinicians to deliver a clear message that nicotine adversely affects health by 
providing unequivocal advice to pregnant women and adolescents to avoid the use of all 
tobacco products, as well as exposure to both secondhand smoke and secondhand aerosol. If 
these measures are accompanied by intensification of established comprehensive tobacco 
control programs as recommended by CDC,(326) they would be expected to have an even 
greater impact.
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Highlights
• Electronic cigarettes are often promoted as a safer alternative to combusted 
cigarettes.
• Human and animal research supports that nicotine contributes to the adverse 
effects of gestational tobacco exposure on fetal development.
• Nicotine exposure during adolescence is associated with cognitive deficits.
• Measures to protect pregnant women and adolescents from nicotine exposure 
are warranted.
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